Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study
Year: 2022
Type: article
Abstract: CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.
Source: British Journal of Haematology
DOI: 10.1111/bjh.18233
Institutions: Sylvester Comprehensive Cancer Center, University Medical Center Hamburg-Eppendorf, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Centre Hospitalier Universitaire de Nantes, Ondokuz Mayıs University, University of Ostrava, University Hospital Ostrava, The University of Queensland, Princess Alexandra Hospital, Yonsei University, Severance Hospital, Amgen (United States), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,800
Awards: G427533880, G6689551747
OpenAlex ID: W4282933375